UCL will study PEX010, the company's botanical psilocybin drug candidate, in trials investigating human perception, cognition, and therapeutic ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...

The combined company will operate under the name 'ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol ...

Today, world-leading sleep fitness company Eight Sleep announced a new and advanced cooling feature will be hitting its smart ...

Raleigh-based Focal Medical, an oncology device company that received early funding from the North Carolina Biotechnology Center, has been acquired by a Florida biopharmaceutical company. Financial ...

SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout ...

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 2, Canaccord ...